Biogen sues Teva over MS generic
18-03-2021
Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic
25-02-2021
nitpicker / Shutterstock.com
The English High Court has found that a challenged claim of Bayer's targeted cancer drug sorafenib is invalid due to obviousness, in a win for Israeli pharmaceutical company Teva Pharmaceuticals.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Bayer, Teva Pharmaceuticals, sorafenib, cancer treatment, tosylate salt, unpatentable, obviousness, prior art, inventive step, patent invalidation
